InvestorsHub Logo
Followers 30
Posts 9030
Boards Moderated 0
Alias Born 12/15/2004

Re: junkmasterg post# 55591

Thursday, 12/13/2007 9:52:49 PM

Thursday, December 13, 2007 9:52:49 PM

Post# of 64738
junkmaster: Sage advice. Had I followed it I would be considerably richer at this point. I let a lot of paper profits in CYGX slip away because of my blind faith in "the science". The same with several other of my biotechs. You might get lucky hodling one of these for the long haul. But you're right. It's a fool's game. The odds are stacked up too high. Lack of money. The FDA. Some argue that CYGX can succeed quicker because they only need to sell a component of a vaccine while the other partnering company will bear the brunt of the research costs on the actual vaccine. But that other company is probably underfunded, undermanned and will take years and years to get their vaccine approved. And until it is approved there will be no large market for synDNA. Even if everything worked out perfectly it would still take at least 5 more years for synDNA to have a real, viable market for a DNA vaccine. Vical is the closest to getting a DNA vaccine to market, and they aren't going to use CYGX. CYGX has two prayers at this point. Miracle #1: The Federal government steps up and gives them a big contract for a Brucellosis vaccine for cattle. Miracle #2: Some other well funded and well run company buys CYGX for a premium, let's say $2.00 a share once the manufacturing facility is completed and FDA certified to be cGMP approved. No other scenario can succeed. They aren't going to develop their own ANYTHING. They don't have the money. Period. End of story. And they can't keep selling private placement shares for 5 more years until there MIGHT be a company willing to use synDNA in an approved vaccine. So it's buy-out or government bailout. Or bust.
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.